Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 4/20 | 0.69 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.69 |
| ▸ | ENPP2 | Q13822 | 8/20 | 0.66 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578581 | 0.88 | ENPP2 (0.70) | LPLLIPGENPP2CYP4F2CYP4A11 | |
| SCHEMBL30445243 | 0.83 | LPL (0.75) | LPLLIPGENPP2MGLL | |
| SCHEMBL18126523 | 0.83 | LPL (0.75) | LPLLIPGENPP2MGLL | |
| SCHEMBL3138179 | 0.83 | LPL (0.90) | LPLLIPGENPP2MGLLCA1 | |
| SCHEMBL16687447 | 0.82 | ENPP2 (0.70) | LPLLIPGENPP2LTA4HEPHX2 | |
| SCHEMBL1997891 | 0.81 | LIPG (1.00) | LPLLIPGENPP2MGLLCA1 | |
| SCHEMBL241880 | 0.81 | CYP4F2 (0.53) | LPLLIPGCYP4F2CYP4A11CA2 | |
| SCHEMBL28980689 | 0.80 | LIPG (1.00) | LPLLIPGENPP2MGLLCA1 | |
| SCHEMBL28980712 | 0.80 | LIPG (1.00) | LPLLIPGENPP2MGLLCA1 | |
| SCHEMBL28980699 | 0.80 | LIPG (1.00) | LPLLIPGENPP2MGLLCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111146496-B | Polymer electrolyte and lithium ion battery containing same | 珠海冠宇电池股份有限公司 | 2021-07-13 | — | — | CN | claimed |
| CN-111146496-A | Polymer electrolyte and lithium ion battery containing same | 珠海冠宇电池有限公司 | 2020-05-12 | — | — | CN | claimed |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners (US) | 2025-04-01 | — | — | US | disclosed |
| CN-119528824-A | 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-01-14 | — | — | US | disclosed |
| CN-113166078-B | 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2024-11-19 | — | — | CN | disclosed |
| WO-2024054840-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230181462-A1 | Dynamic Covalent Hydrogels, Precursors Thereof and Uses Thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-06-15 | — | — | US | disclosed |
| WO-2007040438-A2 | NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| WO-2006083538-A1 | AMINOALKYLPHENYL INDOLONE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173192-A1 | Aminoalkylphenyl indolone derivatives | H. LUNDBECK A/S | 2006-08-03 | — | — | US | disclosed |
| EP-1644358-A2 | BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1572693-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005007648-A2 | BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | PHARMACIA CORPORATION | 2004-10-21 | — | — | US | disclosed |
| WO-2004058762-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | LPL 3708/4885LIPG 1899/4885ENPP2 1400/4885 |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | LPL 79/4885LIPG 47/4885ENPP2 83/4885 |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | MAPKAPK2, MAP3K2, MKNK2 | LPL 1919/4885LIPG 2219/4885ENPP2 477/4885 |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | LPL 79/4885LIPG 47/4885ENPP2 83/4885 |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | LPL 79/4885LIPG 47/4885ENPP2 83/4885 |
| US-20230181462-A1 | Dynamic Covalent Hydrogels, Precursors Thereof and Uses Thereof | CDC37, ILK, PTMS | LPL 4164/4885LIPG 3049/4885ENPP2 3237/4885 |
| US-20060173192-A1 | Aminoalkylphenyl indolone derivatives | GALR3, HTR3E, HTR3C | LPL 1699/4885LIPG 3562/4885ENPP2 461/4885 |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | LPL 1429/4885LIPG 1751/4885ENPP2 484/4885 |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | LPL 2728/4885LIPG 1858/4885ENPP2 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.